Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Research Objective
3.4 Assumptions & Limitations
3.4.1 Assumptions
3.4.2 Limitations
3.5 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Increasing Number of Pet Owners
5.2.2 Growing Livestock Population and Disease Outbreaks
5.2.3 Advances in Technology underlying Veterinary Vaccines
5.2.4 Various Initiatives by Several Government Agencies, Animal Associations, and Prominent Market Players
5.3 Restraint
5.3.1 High Storage Cost associated with Veterinary Vaccines
5.4 Opportunity
5.4.1 Rising Investments to Improve Animal Health
6 Market Factor Analysis
6.1 Porter's Five Forces Model
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Buyers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitutes
6.1.5 Rivalry
6.2 Supply Chain Analysis
6.2.1 R&D and Development
6.2.2 Manufacturing
6.2.3 Distribution & Sales
6.2.4 Post-Sales Monitoring
7 Global Veterinary/Animal Vaccines Market, by Type
7.1 Introduction
7.1.1 Livestock Vaccines
7.1.2 Porcine Vaccines
7.1.3 Companion Animal Vaccines
7.1.4 Poultry Vaccines
7.1.5 Aquaculture Vaccines
8 Global Veterinary/Animal Vaccines Market, by Technology
8.1 Introduction
8.1.1 Live Attenuated Vaccines
8.1.2 Inactivated Vaccines
8.1.3 Recombinant Vaccines
8.1.4 Toxoid Vaccines
9 Global Veterinary/Animal Vaccines Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 France
9.3.1.2 Germany
9.3.1.3 UK
9.3.1.4 Spain
9.3.1.5 Italy
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East and Africa
9.5.1 Middle East
9.5.2 Africa
10 Competitive Landscape
10.1 Introduction
11 Company Profiles
11.1 Boehringer Ingelheim International GmbH
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products/Services Offered
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategies
11.2 Zoetis
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products/Services Offered
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategies
11.3 Ceva
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products/Services Offered
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategies
11.4 MSD & Co. Inc.
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products/Services Offered
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategies
11.5 Elanco
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products/Services Offered
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategies
11.6 Virbac
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products/Services Offered
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategies
11.7 Phibro Animal Health Corporation.
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products/Services Offered
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategies
11.8 Hipra
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products/Services Offered
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategies
11.9 IDT Biologika GmbH
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products/Services Offered
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategies
11.1 Biogenesis Bago SA
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products/Services Offered
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategies
12 Appendix
12.1 Discussion Blue Print